



(51) International Patent Classification:

A61M 37/00 (2006.01) *A61M 5/142* (2006.01)
A61M 5/168 (2006.01) *G06F 19/00* (2011.01)

(21) International Application Number:

PCT/US2012/028399

(22) International Filing Date:

9 March 2012 (09.03.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/470,340 31 March 2011 (31.03.2011) US
13/249,975 30 September 2011 (30.09.2011) US

(71) Applicant (*for all designated States except US*): **INCLINE THERAPEUTICS, INC.** [US/US]; 900 Saginaw Drive, Suite 200, Redwood City, CA 94063 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **LEMKE, John** [US/US]; 900 Saginaw Drive, Suite 200, Redwood City, CA 94063 (US). **SATRE, Scot** [US/US]; 900 Saginaw Drive, Suite 200, Redwood, CA 94063 (US). **CHEN, Corinna, X.** [US/US]; 900 Saginaw Drive, Suite 200, Redwood City, CA 94063 (US). **READ, Brian, W.** [US/US]; 900 Saginaw Drive, Suite 200, Redwood City, CA 94063 (US).

(74) Agents: **GLENN, W., Benjamin** et al.; Shay Glenn LLP, 2755 Campus Drive, Suite 210, San Mateo, CA 94403 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

(54) Title: SWITCH VALIDATION CIRCUIT AND METHOD

(57) Abstract: A switch operated therapeutic agent delivery device is described. Embodiments of the operated therapeutic agent delivery device include a switch that can be operated by a user, a device controller connected to the switch through a switch input where the device can actuate the device when certain predetermined conditions are met, and a switch integrity subcircuit which is used to detect a fault or a precursor to a fault.

